EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> DBV Technologies filed a biologics license application for Viaskin Peanut. The submission features data intended to address the FDA’s issues with the original filing. Statement  

> A phase 2b/3 trial of TopiVert Pharma’s treatment for dry eye disease missed its primary endpoints. TopiVert plans to run another study of the drug. Release 

> ObsEva secured a $75 million credit facility with Oxford Finance. The Swiss company will use the money to fund phase 3 trials. Statement 

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

> MorphoSys signaled its intention to file for approval of tafasitamab in Europe. The plan is to complete the submission around the middle of next year. Release

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.